Aligos Therapeutics (NASDAQ:ALGS) Issues Earnings Results

Aligos Therapeutics (NASDAQ:ALGS) issued its quarterly earnings data on Friday. The company reported ($2.09) EPS for the quarter, topping analysts’ consensus estimates of ($2.28) by $0.19, FiscalAI reports. The firm had revenue of $2.87 million during the quarter, compared to analyst estimates of $4.85 million. Aligos Therapeutics had a negative return on equity of 160.72% and a negative net margin of 241.01%.

Aligos Therapeutics Stock Performance

Aligos Therapeutics stock opened at $4.07 on Friday. Aligos Therapeutics has a fifty-two week low of $3.98 and a fifty-two week high of $13.69. The stock has a market cap of $25.40 million, a PE ratio of -0.64 and a beta of 2.43. The firm’s 50-day simple moving average is $5.31 and its 200 day simple moving average is $6.17.

Analysts Set New Price Targets

Several research analysts recently issued reports on ALGS shares. Weiss Ratings cut Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 16th. HC Wainwright reiterated a “buy” rating on shares of Aligos Therapeutics in a report on Monday, August 10th. Finally, Jefferies Financial Group raised Aligos Therapeutics to a “strong-buy” rating in a research report on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Aligos Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $38.50.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for viral infections and liver diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and selected respiratory viral infections.

Aligos’ pipeline has included investigational therapies such as ALG-000184, an oral capsid assembly modulator being developed for chronic HBV, and ALG-055009, an oral thyroid hormone receptor beta agonist under evaluation for MASH.